Biohydrogen production in an outdoor panel photobioreactor on dark fermentation effluent of molasses

Hydrogen is regarded as an ideal energy carrier if it is produced from renewable resources such as biomass. Sequential operation of dark and photofermentation allows a highly efficient production of hydrogen from biomass, as maximal conversion of the energy in the carbohydrates to hydrogen can be achieved. In this study photofermentative hydrogen production was carried out in a solar panel photobioreactor by Rhodobacter capsulatus wild type (DSM 1710) and Rhodobacter capsulatus hup(-) (YO3) strain on the molasses dark fermentation effluents which were obtained using an extreme thermophile Caldicellusiruptor saccharolyticus in the dark fermentation step. Continuous hydrogen production on the molasses dark fermentation effluents was achieved up to 55 days with R. capsulatus wild type and 75 days with R. capsulatus hup(-) in outdoor conditions during summer 2009, in Ankara Turkey. The maximum hydrogen yield obtained using R. capsulatus hup- was 78% (of the theoretical maximum) and the maximum hydrogen productivity was 0.67 mmol H-2/L-c.h. The maximum hydrogen productivity and yield of the wild type strain on the molasses dark fermentation effluents were 0.50 mmol H-2/L-c.h and 50%, respectively. The changes in climatic conditions, particularly daily global solar radiation, affected the hydrogen productivity and yield. Copyright (C) 2011, Hydrogen Energy Publications, LLC. Published by Elsevier Ltd. All rights reserved

The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort

Background and Aim: The aims of the present study were to evaluate the real-life efficacy and tolerability of glecaprevir (GLE)/pibrentasvir (PIB) in the treatment of patients with chronic hepatitis C (CHC). Materials and Methods: Between May 2019 and May 2022, 686 patients with CHC, treated with GLE/PIB combination from 21 participating centers in Turkiye, were enrolled in the study. Results: All patients were Caucasian, and their median age was 56 years. At the start of GLE/PIB treatment, the median serum Hepatitis C virus RNA and serum alanine amino transaminase (ALT) levels were 6.74 log10 IU/mL and 47 U/L, respectively. Fifty-three percent of the patients were infected with genotype 1b, followed by genotype 3 (17%). Diabetes was the more common concomitant disease. The sustained virological response (SVR12) was 91.4% with intent-to-treat analysis and 98.5% with per protocol analysis. The SVR12 rates were statistically significant differences between the patients who were i.v. drug users and non-user (88.0% vs. 98.8%, p=0.025). From the baseline to SVR12, the serum ALT levels and Model for End-Stage Liver Disease score were significantly improved (p<0.001 and p=0.014, respectively). No severe adverse effect was observed. Conclusion: GLE/PIB is an effective and tolerable treatment in patients with CHC